乳腺癌患者的围手术期基因检测与手术时间
本研究回顾性分析了2022年6月至12月接受 upfront 手术的0-3期乳腺癌患者492例(女性489例),评估遗传学评估对从初次手术访视到手术时间间隔的影响。结果显示,接受基因检测的患者手术时间为33天,未接受检测者为34天(P=0.45),遗传学评估和基因检测似乎并未延迟治疗时间。
要点
- 在492例患者中,281例(57.1%)符合NCCN基因检测标准,199例(72.4%)咨询了遗传咨询师。
- 接受基因检测者手术时间33天 vs 未检测者34天(P=0.45),未见显著延迟。
- 26例(11.9%)检出致病或可能致病变异,其中3例(11.5%)因此改变了初始手术方案。
核心结论
- 在本研究队列中,遗传性乳腺癌评估和基因检测似乎并未延迟乳腺癌患者的治疗时间。
研究设计与样本
- 回顾性综述,纳入2022年6月至2022年12月期间接受 upfront 手术的0-3期乳腺癌患者,共492例(女性489例)。
主要发现
- 81例(16.2%)诊断时年龄≤50岁;281例(57.1%)符合NCCN基因检测标准,其中199例(72.4%)咨询了遗传咨询师;76例(27.6%)不符合NCCN标准者 pursued 遗传咨询。
- 218例(79.3%)被转诊进行遗传咨询的患者完成了检测;基因检测结果的平均周转时间为11天(范围6-66天)。
- 26例(11.9%)检出致病或可能致病变异,其中24例(92.3%)符合NCCN检测标准,2例(7.7%)不符合。
- 接受基因检测的患者手术时间为33天,未接受检测者为34天(P=0.45)。
- 3例(11.5%)携带致病或可能致病变异的患者因基因检测结果改变了初始手术方案;7例致病或可能致病变异结果在术后返回的患者未接受额外手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Time to treatment has been identified as a quality metric, with longer time to treatment associated with poorer outcomes. Genetic evaluation is an integral part of treatment counseling for patients with breast cancer. With expanding indications for genetic testing and consideration of expansion of genetic testing to all patients with a personal history of breast cancer, this study aims to evaluate the effect of genetic evaluation on the time interval from initial surgical visit to surgery. METHODS: A retrospective review of patients undergoing upfront surgery for stage 0-3 breast cancer from June 2022 to December 2022. Patient demographics, treatment characteristics, National Comprehensive Cancer Network criteria for genetic testing, and results were obtained. RESULTS: The study included 492 patients (489 females). Eighty-one (16.2%) were ≤50 years of age at diagnosis. In total, 281 patients (57.1%) met National Comprehensive Cancer Network criteria for genetic testing and 199 consulted with a genetic counselor (72.4%). Seventy-six patients (27.6%) not meeting National Comprehensive Cancer Network criteria pursued genetic counseling. In total, 218 patients (79.3%) referred for genetic counseling completed testing. Mean turnaround time to genetic testing result was 11 days (range, 6-66 days). Twenty-six patients (11.9%) had a pathogenic or likely pathogenic variant. Twenty-four of these patients met National Comprehensive Cancer Network testing criteria (92.3%) and 2 did not (7.7%). The time to treatment for patients undergoing genetic testing was 33 vs 34 days in those without testing (P = .45). Three patients (11.5%) with pathogenic or likely pathogenic variants altered their initial surgical plan due to their genetic testing results. Seven patients with pathogenic or likely pathogenic variant results returning postoperatively did not undergo additional surgery. CONCLUSION: Hereditary breast cancer evaluation and genetic testing did not appear to delay time to treatment for patients with breast cancer in our study cohort.
引用
- Wu V, Chichura AM, Dickard J, et al. Perioperative genetic testing and time to surgery in patients with breast cancer. Surgery. 2023. PMID: 37848355. doi:10.1016/j.surg.2023.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。